it managed? Heart 2015; 101:1240–1249.
7 7 Buntinx F, Knockaert D, de Blaey N, et al. Chest pain in general practice or in the hospital emergency department: is it the same? Fam Pract 2002; 18:586–589.
8 8 Svavarsdóttir AE, Jónasson MR, Gudmundsson GH, et al. Chest pain in family practice: Diagnosis and long‐term outcome in a community setting. Can Fam Physician 1996; 42:1672.
9 9 Klinkman MS, Stevens D, Gorenflo DW. Episodes of care for chest pain: a preliminary report from MIRNET. Michigan Research Network. J Fam Pract 1994; 38:345–352.
10 10 Bösner S, Becker A, Haasenritter J, et al. Chest pain in primary care: Epidemiology and pre‐work‐up probabilities. Eur J Gen Pract 2009; 15:141–146.
11 11 Ebell MH. Evaluation of chest pain in primary care patients. Am Fam Physician 2011; 83:603–605.
12 12 Hoorweg BBN, Willemsen RTA, Cleef LE, et al. Frequency of chest pain in primary care, diagnostic tests performed and final diagnoses. Heart 2017; 103:1727–1732.
13 13 Hsia RY, Hale Z, Tabas JA. A national study of the prevalence of life‐threatening diagnoses in patients with chest pain. JAMA Intern Med 2016; 176:1029.
14 14 Locke GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population‐based study in Olmsted County, Minnesota. Gastroenterology 1997; 112:1448–1456.
15 15 Eslick GD, Jones MP, Talley NJ. Non‐cardiac chest pain: prevalence, risk factors, impact and consulting ‐ a population‐based study. Aliment Pharmacol Ther 2003; 17:1115–1124.
16 16 Chiocca J, Olmos J, Salis G, et al. Prevalence, clinical spectrum and atypical symptoms of gastro‐oesophageal reflux in Argentina: a nationwide population‐based study. Aliment Pharmacol Ther 2005; 22:331–342.
17 17 Wong WM, Lai KC, Lam KF, et al. Prevalence, clinical spectrum and health care utilization of gastro‐oesophageal reflux disease in a Chinese population: a population‐based study. Aliment Pharmacol Ther 2003; 18:595–604.
18 18 Tew R, Guthrie EA, Creed FH, et al. A long‐term follow‐up study of patients with ischaemic heart disease versus patients with nonspecific chest pain. J Psychosom Res 1995; 39:977–985.
19 19 Mudipalli RS, Remes‐Troche JM, Andersen L, et al. Functional Chest Pain. J Clin Gastroenterol 2007; 41:264–269.
20 20 Clouse RE, Lustman PJ. Psychiatric illness and contraction abnormalities of the esophagus. N Engl J Med 1983; 309:1337–1342.
21 21 Fleet RP, Dupuis G, Marchand A, et al. Panic disorder in emergency department chest pain patients: Prevalence, comorbidity, suicidal ideation, and physician recognition. Am J Med 1996; 101:371–380.
22 22 Kahn SE. The challenge of evaluating the patient with chest pain. Arch Pathol Lab Med 2000; 124:1418–1419.
23 23 Demeester T, O’Sullivan G, Bermudez G, et al. Esophageal function in patients with angina‐type chest pain and normal coronary angiograms. Ann Surg 1982; 196:488–498.
24 24 Hewson, EG, Sinclair JW, Dalton CB, et al. Twenty‐four‐hour esophageal pH monitoring: The most useful test for evaluating noncardiac chest pain. Am J Med 1991; 90:576–583.
25 25 Rosztóczy A, Vass A, Izbéki F, et al. The evaluation of gastro‐oesophageal reflux and oesophagocardiac reflex in patients with angina‐like chest pain following cardiologic investigations. Int J Cardiol 2007; 118:62–68.
26 26 Singh S. The contribution of gastroesophageal reflux to chest pain in patients with coronary artery disease. Ann Intern Med 1992; 117:824.
27 27 Richter JE, Hewson EG, Sinclair JW, et al. Acid perfusion test and 24–hour esophageal pH monitoring with symptom index. Dig Dis Sci 1991; 36:565–571.
28 28 Chauhan A, Mullins PA, Taylor G, et al. Cardioesophageal reflex: A mechanism for “linked angina” in patients with angiographically proven coronary artery disease. J Am Coll Cardiol 1996; 27:1621–1628.
29 29 Hu WHC, Martin CJ, Talley NJ. Intraesophageal acid perfusion sensitizes the esophagus to mechanical distension: a Barostat study. Am J Gastroenterol 2000; 95:2189–2194.
30 30 Achem SR, Kolts BE, MacMath T, et al. Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sci 1997; 42:2138–2145.
31 31 Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 1998; 115:42–49.
32 32 Ofman JJ, Gralnek IM, Udani J, et al. The cost‐effectiveness of the omeprazole test in patients with noncardiac chest pain. Am J Med 1999; 107:219–227.
33 33 Xia HHX, Lai KC, Lam SK, et al. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy‐negative patients with non‐cardiac chest pain. Aliment Pharmacol Ther 2003; 17:369–377.
34 34 Dickman R, Emmons S, Cui H, et al. The effect of a therapeutic trial of high‐dose rabeprazole on symptom response of patients with non‐cardiac chest pain: a randomized, double‐blind, placebo‐controlled, crossover trial. Aliment Pharmacol Ther 2005; 22:547–555.
35 35 Kim JH, Sinn DH, Son HJ, et al. Comparison of one‐week and two‐week empirical trial with a high‐dose rabeprazole in non‐cardiac chest pain patients. J Gastroenterol Hepatol 2009; 24:1504–1509.
36 36 Cremonini F, Wise J, Moayyedi P, et al. Diagnostic and therapeutic use of proton pump inhibitors in non‐cardiac chest pain: a metaanalysis. Am J Gastroenterol 2005; 100:1226–1232.
37 37 Wang WH, Huang JQ, Zheng GF, et al. Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with non‐cardiac chest pain? Arch Intern Med 2005; 165:1222.
38 38 Richter JE, Pandolfino JE, Vela MF, et al. Utilization of wireless pH monitoring technologies: A summary of the proceedings from the Esophageal Diagnostic Working Group. Dis Esophagus 2013; 26:755–765.
39 39 Bredenoord AJ, Weusten BLAM, Timmer R, et al. Addition of esophageal impedance monitoring to pH monitoring increases the yield of symptom association analysis in patients off PPI therapy. Am J Gastroenterol 2006; 101:453–459.
40 40 Prakash C, Clouse RE. Wireless pH monitoring in patients with non‐cardiac chest pain. Am J Gastroenterol 2006; 101:446–452.
41 41 Tseng D, Rizvi AZ, Fennerty MB, et al. Forty‐eight‐hour pH monitoring increases sensitivity in detecting abnormal esophageal acid exposure. J Gastrointest Surg 2005; 9:1043–1052.
42 42 Scarpulla G, Camilleri S, Galante P, et al. The impact of prolonged pH measurements on the diagnosis of gastroesophageal reflux disease: 4–day wireless pH studies. Am J Gastroenterol 2007; 102:2642–2647.
43 43 Hirano I, Zhang Q, Pandolfino JE, et al. Four‐day bravo pH capsule monitoring with and without proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2005; 3:1083–1088.
44 44 Savarino E, Bredenoord AJ, Fox M, et al. Expert consensus document: Advances in the physiological assessment and diagnosis of GERD. Nat Rev Gastroenterol Hepatol 2017; 14:665–676.
45 45 Hemmink GJM, Bredenoord AJ, Weusten BLAM, et al. Esophageal pH‐impedance monitoring in patients with therapy‐resistant reflux symptoms: ‘On’ or ‘Off’ proton pump inhibitor? Am J Gastroenterol 2008; 103:2446–2453.
46 46 Mainie I, Tutuian R, Shay S, et al. Acid and non‐acid reflux in patients with persistent symptoms despite acid suppressive therapy: A multicentre study using combined ambulatory impedance‐pH monitoring. Gut 2006; 55:1398–1402.
47 47 Zerbib F, Roman S, Ropert A, et al. Esophageal pH‐impedance monitoring and symptom analysis in GERD: A study in patients off and on therapy. Am J Gastroenterol 2006; 101:1956–1963.
48 48 Kondo T, Miwa H. The role of esophageal hypersensitivity in functional heartburn. J Clin Gastroenterol 2017; 51:571–578.
49 49 Knowles CH, Aziz Q. Visceral hypersensitivity in non‐erosive reflux disease.